A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment

NCT06247085 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Homocystinuria

Interventions

DRUG: Pegtibatinase
OTHER: Placebo

Sponsor

Travere Therapeutics, Inc.